Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 113
Filtrar
Más filtros

Base de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Endocrinol Invest ; 46(2): 319-326, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35988109

RESUMEN

PURPOSE: Previous studies demonstrated decreased quality of life (QoL) in differentiated thyroid cancer (DTC) survivors and suggested QoL variability related to time from thyroidectomy and levothyroxine dosage. The aims of this study were to evaluate QoL in thyroidectomized subjects in different levothyroxine states and to evaluate the association between TSH and thyroid hormones and QoL. METHODS: Prospective 5-year study enrolling 208 patients thyroidectomized for DTC, studied in one to four times according to levothyroxine dosage: withdrawal (WITHD), complete (C-SUPP) and mild TSH-suppression (M-SUPP), replacement (REPL). Each patient was allowed to participate into the study more than one time. A total of 300 evaluations were collected, consisting of detailed thyroid hormone profile and QoL assessment through the ThyPRO questionnaire. RESULTS: Comparing the four groups, significant differences were found for anxiety, impaired social and daily life and item 12 (overall impact of thyroid disease) domains (p < 0.05). Interestingly, C-SUPP subjects reported the best scores in almost all ThyPRO scales. Significant correlations were found between QoL and pituitary-thyroid axis function, as well as between QoL and gender, being females more affected. At multiple regression analyses fT3 demonstrated to be the best explanatory factor for overall impact of thyroid disease on the patient's life, followed by gender. CONCLUSIONS: TSH-suppressive doses of levothyroxine are more effective in improving QoL in DTC patients after thyroidectomy. These results confirm the urgent need of further studies aimed to define the best treatment of hypothyroidism, effective on well-being and harmless for patients.


Asunto(s)
Enfermedades de la Tiroides , Neoplasias de la Tiroides , Femenino , Humanos , Masculino , Tiroxina , Calidad de Vida , Tiroidectomía , Estudios Prospectivos , Neoplasias de la Tiroides/tratamiento farmacológico , Neoplasias de la Tiroides/cirugía , Hormonas Tiroideas/uso terapéutico , Enfermedades de la Tiroides/tratamiento farmacológico , Tirotropina
2.
Eur Phys J C Part Fields ; 75(11): 554, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26692817

RESUMEN

This review summarizes the results of the activities which have taken place in 2014 within the Standard Model Working Group of the "What Next" Workshop organized by INFN, Italy. We present a framework, general questions, and some indications of possible answers on the main issue for Standard Model physics in the LHC era and in view of possible future accelerators.

3.
J Microsc ; 252(3): 226-50, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24111790

RESUMEN

Light widefield microscopes and digital imaging are the basis for most of the analyses performed in every biological laboratory. In particular, the microscope's user is typically interested in acquiring high-detailed images for analysing observed cells and tissues, meanwhile being representative of a wide area to have reliable statistics. The microscopist has to choose between higher magnification factor and extension of the observed area, due to the finite size of the camera's field of view. To overcome the need of arrangement, mosaicing techniques have been developed in the past decades for increasing the camera's field of view by stitching together more images. Nevertheless, these approaches typically work in batch mode and rely on motorized microscopes. Or alternatively, the methods are conceived just to provide visually pleasant mosaics not suitable for quantitative analyses. This work presents a tool for building mosaics of images acquired with nonautomated light microscopes. The method proposed is based on visual information only and the mosaics are built by incrementally stitching couples of images, making the approach available also for online applications. Seams in the stitching regions as well as tonal inhomogeneities are corrected by compensating the vignetting effect. In the experiments performed, we tested different registration approaches, confirming that the translation model is not always the best, despite the fact that the motion of the sample holder of the microscope is apparently translational and typically considered as such. The method's implementation is freely distributed as an open source tool called MicroMos. Its usability makes building mosaics of microscope images at subpixel accuracy easier. Furthermore, optional parameters for building mosaics according to different strategies make MicroMos an easy and reliable tool to compare different registration approaches, warping models and tonal corrections.


Asunto(s)
Biología/métodos , Procesamiento de Imagen Asistido por Computador/métodos , Microscopía/métodos , Imagen Óptica/métodos , Programas Informáticos
4.
J Microsc ; 248(1): 6-22, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22900940

RESUMEN

Vignetting is the radial attenuation effect of the image's brightness intensity from the center of the optical axis to the edges. To perform quantitative image analyses it is mandatory to take into account this effect, intrinsic of the acquisition system. Many image processing steps, such as segmentation and object tracking, are strongly affected by vignetting and the effect becomes particularly evident in mosaicing. The most common approach to compensate the attenuation of the image's brightness intensity is to estimate the vignetting function from a homogeneous reference object, typically an empty field, and to use it to normalize the images acquired under the same microscope set-up conditions. However, several reasons lead to the use of image-based methods to estimate the vignetting function from the images themselves. In this work, we propose an effective multi-image based method suitable for real-time applications. It is designed to correct vignetting in wide field light microscopy images. The vignetting function is computed stemming from a background built incrementally from the proposed background segmentation algorithm, validated on several manually segmented images. The extensive experiments carried out using cell cultures, histological samples and synthetic images prove that our method almost always yields the best results and in worst cases are comparable to those achieved by using homogeneous reference objects.


Asunto(s)
Microscopía/métodos , Manejo de Especímenes/métodos , Técnicas Citológicas/métodos , Histocitoquímica/métodos , Modelos Teóricos , Proyectos de Investigación
5.
Phys Rev Lett ; 103(16): 162001, 2009 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-19905690

RESUMEN

The X(3872) is universally accepted to be an exotic hadron. In this Letter, we assume that the X(3872) is a D(0)D(*0) molecule, as claimed by many authors, and attempt an estimate of its prompt production cross section at the Fermilab Tevatron. A comparison with Collider Detector at Fermilab data allows us to draw rather compelling quantitative conclusions about this statement.

6.
Phys Rev Lett ; 93(21): 212002, 2004 Nov 19.
Artículo en Inglés | MEDLINE | ID: mdl-15600998

RESUMEN

Light scalar mesons are found to fit rather well a diquark-antidiquark description. The resulting nonet obeys mass formulas which respect, to a good extent, the Okubo-Zweig-Iizuka (OZI) rule. OZI allowed strong decays are reasonably reproduced by a single amplitude describing the switch of a qq pair, which transforms the state into two colorless pseudoscalar mesons. Predicted heavy states with one or more quarks replaced by charm or beauty are briefly described; they should give rise to narrow states with exotic quantum numbers.

7.
J Soc Gynecol Investig ; 10(7): 438-42, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14519486

RESUMEN

OBJECTIVE: Few clinical trials have examined the effects of nitric oxide donors on the human cervix. We address the question of the ultrastructural and clinical effects of topical NO donor on the nonpregnant human cervix. METHODS: Twenty patients admitted to the hospital for hysterectomy were randomly assigned to receive either placebo gel or 1% nitroprusside-based gel into the cervical canal. After surgery, a small biopsy of the cervical canal was taken and analyzed by electron microscopy. Vital parameters were monitored after application. RESULTS: In the placebo group, the connective tissue was normal. In the experimental group, the collagen fibers were widely spaced, and no longitudinal collagen bundles were visible. Macrophages, leukocytes, and activated fibroblasts in treated tissues demonstrated a proinflammatory reaction. Adverse effects were reported in a minority of subjects. No significant changes in blood pressure or in nitrite and nitrate levels were reported. CONCLUSION: In both fertile and postmenopausal women, cervical sodium nitroprusside induced morphologic changes similar to those reported for the ripening process.


Asunto(s)
Maduración Cervical/efectos de los fármacos , Nitroprusiato/administración & dosificación , Adulto , Cuello del Útero/efectos de los fármacos , Cuello del Útero/ultraestructura , Colágeno/análisis , Colágeno/ultraestructura , Femenino , Fibroblastos/ultraestructura , Humanos , Histerectomía , Leucocitos/ultraestructura , Macrófagos/ultraestructura , Menopausia , Microscopía Electrónica , Persona de Mediana Edad , Nitroprusiato/efectos adversos , Placebos , Embarazo
8.
J Matern Fetal Neonatal Med ; 11(2): 84-8, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-12375548

RESUMEN

OBJECTIVE: To investigate the efficacy of intrapartum vaginal flushings with chlorhexidine compared with ampicillin in preventing group B streptococcus transmission to neonates. METHODS: This was a randomized controlled study, including singleton pregnancies delivering vaginally. Rupture of membranes, when present, must not have occurred more than 6 h previously. Women with any gestational complication, with a newborn previously affected by group B streptococcus sepsis or whose cervical dilatation was greater than 5 cm were excluded. A total of 244 group B streptococcus-colonized mothers at term (screened at 36-38 weeks) were randomized to receive either 140 ml chlorhexidine 0.2% by vaginal flushings every 6 h or ampicillin 2 g intravenously every 6 h until delivery. Neonatal swabs were taken at birth, at three different sites (nose, ear and gastric juice). RESULTS: A total of 108 women were treated with ampicillin and 109 with chlorhexidine. Their ages and gestational weeks at delivery were similar in the two groups. Nulliparous women were equally distributed between the two groups (ampicillin, 87%; chlorhexidine, 89%). Clinical data such as birth weight (ampicillin, 3,365 +/- 390 g; chlorhexidine, 3,440 +/- 452 g), Apgar scores at 1 min (ampicillin, 8.4 +/- 0.9; chlorhexidine, 8.2 +/- 1.4) and at 5 min (ampicillin, 9.7 +/- 0.6; chlorhexidine, 9.6 +/- 1.1) were similar for the two groups, as was the rate of neonatal group B streptococcus colonization (chlorhexidine, 15.6%; ampicillin, 12%). Escherichia coli, on the other hand, was significantly more prevalent in the ampicillin (7.4%) than in the chlorhexidine group (1.8%, p < 0.05). Six neonates were transferred to the neonatal intensive care unit, including two cases of early-onset sepsis (one in each group). CONCLUSIONS: In this carefully screened target population, intrapartum vaginal flushings with chlorhexidine in colonized mothers display the same efficacy as ampicillin in preventing vertical transmission of group B streptococcus. Moreover, the rate of neonatal E. coli colonization was reduced by chlorhexidine.


Asunto(s)
Ampicilina/uso terapéutico , Clorhexidina/administración & dosificación , Infecciones Estreptocócicas/prevención & control , Infecciones Estreptocócicas/transmisión , Streptococcus agalactiae , Administración Intravaginal , Adulto , Escherichia coli/aislamiento & purificación , Femenino , Humanos , Recién Nacido , Transmisión Vertical de Enfermedad Infecciosa , Trabajo de Parto , Paridad , Embarazo , Streptococcus agalactiae/aislamiento & purificación , Factores de Tiempo , Vagina/microbiología
9.
Gynecol Endocrinol ; 16(1): 39-43, 2002 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11915580

RESUMEN

Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment. However, in vivo and in vitro studies have demonstrated that myometrial cells are also targets of the relaxant effects of nitric oxide (NO). The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF). A total of 24 patients with the diagnosis of severe primary dysmenorrhea were studied during two consecutive menstrual cycles. In an open, cross-over, controlled design, patients were randomized to receive either DCF per os or GTN patches the first days of menses, when menstrual cramps became unendurable. In the subsequent cycle the other treatment was used. Patients received up to 3 doses/day of 50 mg DCF or 2.5 mg/24 h transdermal GTN for the first 3 days of the cycle, according to their needs. The participants recorded menstrual symptoms and possible side-effects at different times (0, 30, 60, 120 minutes) after the first dose of medication on the first day of the cycle, with both drugs. The difference in pain intensity score (DPI) was the main outcome variable. Both treatments significantly reduced DPI by the 30th minute (GTN, -12.8 +/- 17.9; DCF, -18.9 +/- 16.6). However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/- 17.9; DFC, -18.9 +/- 16.6 and after two hours: GTN, -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001). Low back pain was also relieved by both drugs. Headache was significantly increased by GTN but not by DCF. Eight patients stopped using GTN because headache--attributed to its use--became intolerable. These findings indicate that GTN has a reduced efficacy and tolerability by comparison with DCF in the treatment of primary dysmenorrhea.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Diclofenaco/administración & dosificación , Dismenorrea/tratamiento farmacológico , Donantes de Óxido Nítrico/uso terapéutico , Nitroglicerina/uso terapéutico , Administración Cutánea , Adulto , Antiinflamatorios no Esteroideos/administración & dosificación , Estudios Cruzados , Diclofenaco/efectos adversos , Diclofenaco/uso terapéutico , Quimioterapia Combinada , Femenino , Cefalea/inducido químicamente , Humanos , Dolor de la Región Lumbar/tratamiento farmacológico , Ciclo Menstrual , Donantes de Óxido Nítrico/administración & dosificación , Nitroglicerina/administración & dosificación , Nitroglicerina/efectos adversos , Dimensión del Dolor
10.
Psychoneuroendocrinology ; 26(7): 721-30, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11500253

RESUMEN

The present study was aimed at investigating a) the risk of having bulimia in a heterogeneous population of secondary amenorrhea; b) the LH and FSH secretion under basal and stimulated conditions (GnRH challenge) according to the presence of bulimic risk in our study population; c) the clinical and endocrine factors predictive of the bulimic risk in amenorrheic women. Amenorrheic women (n=73; age: 23.1+/-4.8 yrs; BMI:20.2+/-2.2 kg/m2) filled in a self rating scale for bulimia (BITE) and were classified accordingly, as being at low risk (score <10), at medium risk (score between 10 and 24), and at high risk (score > or =25) of having bulimia. In each subject basal mean plasma LH levels were calculated over one hour, sampling every 10 minutes, while in a subgroup of 45 patients the area under the curve (AUC) of plasma LH and FSH levels following a challenge with two doses of GnRH (10+10 microg, every two hours), sampling every 15 minutes, was also evaluated. High risk of bulimia was present in 12.3% of the population whereas 45.2% showed a low risk and 42.5% were at medium risk of developing the disorder. Mann-Whitney U test revealed that basal LH values were differently distributed with significantly lower levels (P<0.046) in amenorrheic women at high risk of bulimia in comparison with amenorrheic women at low risk. The AUC of LH secretion following the first challenge of GnRH was significantly higher in amenorrheic women with a high risk of bulimia in respect with both groups of women at low (P<0.034) and medium (P<0.009) risk. A similar result was found with FSH AUC following the first GnRH challenge (P<0.04 high risk vs low risk and P<0.014 high risk vs medium risk). In a multiple regression analysis, the best model predicting the risk of bulimia (BITE total score) included both the LH response to GnRH challenge and BMI. In conclusion, when facing secondary amenorrhea at first consultation, long before a precise pathophysiologic diagnosis of the disease, low basal plasma LH levels and LH response to GnRH challenge may allow one to suspect the presence of abnormal eating pattern of bulimic type.


Asunto(s)
Amenorrea/metabolismo , Amenorrea/psicología , Bulimia/metabolismo , Bulimia/psicología , Hormona Luteinizante/metabolismo , Hipófisis/metabolismo , Adulto , Área Bajo la Curva , Índice de Masa Corporal , Femenino , Hormona Folículo Estimulante/sangre , Hormona Liberadora de Gonadotropina , Humanos , Valor Predictivo de las Pruebas , Escalas de Valoración Psiquiátrica , Análisis de Regresión , Factores de Riesgo
11.
Clin Lab Haematol ; 23(2): 131-4, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11488853

RESUMEN

Platelet function was studied in 30 pregnant women: 14 normotensive (C), and 16 affected by pregnancy-induced hypertension (PIH). Platelet aggregometry (PA) on platelet-rich plasma according to Born was compared with the new PFA-100 System (Dade International Inc, Miami, USA). This device evaluates platelet function (expressed in seconds as closure time, CT) in anticoagulated whole blood ex vivo at high shear rates. PA (expressed as percentage of light transmission) and CT were measured at baseline and after incubation with L-Arginine (L-Arg). MANOVA for repeated measures showed that L-Arg incubation significantly decreased PA (F=7.2, P < 0.05) and increased CT (F=6.05, P < 0.05) in the whole population of pregnant women. Moreover, we analysed separately both parameters in C and in PIH subjects. No differences in PA were found in both groups, neither at baseline nor after L-Arginine incubation. In contrast, CT was significantly longer in PIH in comparison to C before (95.9 s vs. 84 s, P < 0.05) as well after (115 s vs. 92 s, P < 0.05) L-Arginine incubation. Data from PFA-100 confirm our previous reports that during pregnancy the L-Arginine: Nitric Oxide pathway regulates platelet function. In hypertensive patients a significant decrease in platelet function was found by using the PFA-100 system.


Asunto(s)
Complicaciones Cardiovasculares del Embarazo/fisiopatología , Presión Sanguínea , Femenino , Humanos , Hipertensión/sangre , Hipertensión/fisiopatología , Agregación Plaquetaria , Embarazo/fisiología , Complicaciones Cardiovasculares del Embarazo/sangre , Reología/instrumentación
12.
Int J Oncol ; 18(6): 1245-9, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11351258

RESUMEN

1-beta-D-arabinofuranosylcytosine (ara-C) is an antimetabolite used for the treatment of acute myelogenous leukemia. The ability of ara-C to kill neoplastic cells has been correlated to the induction of apoptosis. The clinical use of ara-C is limited by the development of drug resistance. Alterations in drug-induced apoptosis play a critical role in ara-C resistance. In particular, the proto-oncogene bcl-2 has been implicated in this phenomenon. To better understand the molecular basis of the role of bcl-2 in ara-C resistance, we investigated the relationship between the cytotoxic effect of ara-C, the expression levels and the subcellular localization of bcl-2 in three human leukemic cell lines (HL-60, KG1, J111). We have also evaluated the effects of ara-C on the J111 leukemic cell line (showing the lowest levels of Bcl-2 and the highest sensitivity to ara-C) overexpressing the bcl-2 oncogene. The model we developed here will allow further studies on the role of post-translational events involving bcl-2 (such as translocation and/or phosphorylation) in the cellular response to ara-C treatment.


Asunto(s)
Antimetabolitos Antineoplásicos/farmacología , Citarabina/farmacología , Células HL-60/efectos de los fármacos , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Supervivencia Celular/efectos de los fármacos , Fragmentación del ADN , Resistencia a Antineoplásicos , Células HL-60/metabolismo , Humanos , Isoenzimas/metabolismo , Proteína Quinasa C/metabolismo , Proteína Quinasa C-alfa , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas c-bcl-2/genética , Transfección
13.
Maturitas ; 38(2): 157-63, 2001 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-11306204

RESUMEN

OBJECTIVE: The aim of the present study was to evaluate how hormone replacement therapy (HRT) could influence the course of primary headaches in postmenopausal women. METHODS: Fifty patients presenting for clinical evaluation of menopausal status and suffering from headache were enrolled. The observational period lasted 7 months during which women filled in a diary with the clinical characteristics of headache attacks (frequency, days with headache, severity) and the analgesic use (no. of analgesic/month). Climacteric symptoms and both anxiety and depression were also measured. At the first visit the patients were divided into two groups: those suffering from migraine without aura (MwA) and those suffering from episodic tension-type headache (ETTH) and separately randomized. After a month of run-in period, they received two different HRT regimen, either: (1) transdermal estradiol 50 mcg every 7 days for 28 days plus medroxyprogesterone acetate (MAP) 10 mg/day from 15th to 28th day, or (2) oral conjugated estrogens 0.625 mg/day for 28 days plus MAP 10 mg/day for the last 14 days. Follow up evaluations were planned after 1, 3 and 6 months of treatment. RESULTS: While we did not observe any significance change regarding headache parameters in ETTH patients during both transdermal and oral treatment, the course of migraine was significantly affected by the route of HRT. Both frequency of attacks (F = 8.5; P < 0.000) and days with headache (F = 6.9; P < 0.000) significantly increased during HRT in the subgroup assuming oral formulation. On the contrary, no changes in the same parameters were found in the group taking transdermal treatment. Moreover, while severity of migraine was unaffected by HRT, analgesic consumption was significantly increased in the subgroup on oral treatment (F = 6.3; P = 0.001). CONCLUSIONS: HRT significantly affects the course of headache in postmenopausal migraine sufferers. Indeed, while the clinical pattern of ETTH remained stable throughout the observational period, patients suffering from MwA worsened their symptoms within the first 3 months of treatment. In particular, the oral route of administration significantly worsened migraine in comparison to the transdermal route.


Asunto(s)
Estradiol/farmacología , Estrógenos Conjugados (USP)/farmacología , Terapia de Reemplazo de Hormonas , Menopausia , Migraña sin Aura/metabolismo , Administración Cutánea , Administración Oral , Estradiol/administración & dosificación , Estrógenos Conjugados (USP)/administración & dosificación , Femenino , Humanos , Medroxiprogesterona/administración & dosificación , Medroxiprogesterona/farmacología , Persona de Mediana Edad , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Cefalea de Tipo Tensional/metabolismo , Resultado del Tratamiento
14.
Hypertens Pregnancy ; 19(3): 323-30, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11118406

RESUMEN

OBJECTIVE: In chronically hypertensive (CH), preeclamptic (PE), and normotensive pregnant women (N), we investigated ex vivo platelet aggregation in response to L-arginine (L-Arg) and sodium nitroprusside (SN), which are respectively the substrate and donor of nitric oxide (NO). METHODS: Platelet aggregation was determined with a dual-channel aggregometer by measuring transmittance of light through the sample in comparison to platelet poor plasma, as a reference. Aggregation induced by adenosine diphosphate was continuously recorded for 3 min and measured before and after preincubation with L-Arg and SN. RESULTS: Preincubation with L-Arg significantly reduced platelet aggregation in N and CH patients (p < 0.05) but not in PE women. Preincubation with SN affected aggregation in PE women also (p < 0.001). No correlation was found between platelet response to L-Arg or SN stimuli and the severity of hypertensive disorders expressed as week of gestation at delivery or birth weight. CONCLUSIONS: The present study demonstrates that a decreased platelet sensitivity to L-Arg characterizes PE women, whereas SN maintains its antithrombotic power. This impairment seems to be specific for PE, because platelets of CH patients utilize L-Arg normally. This finding supports the involvement of the L-Arg-NO pathway in the pathogenesis of the procoagulative features of PE and probably in the onset of the disease. The maintained response to SN in PE patients suggests a possible therapeutical use of NO donors in the disease.


Asunto(s)
Antihipertensivos/farmacología , Arginina/farmacología , Hipertensión/metabolismo , Donantes de Óxido Nítrico/farmacología , Nitroprusiato/farmacología , Agregación Plaquetaria/efectos de los fármacos , Preeclampsia/metabolismo , Complicaciones Cardiovasculares del Embarazo/metabolismo , Adulto , Análisis de Varianza , Peso al Nacer , Presión Sanguínea , Estudios de Casos y Controles , Cesárea/estadística & datos numéricos , Enfermedad Crónica , Estudios Transversales , GMP Cíclico/metabolismo , Femenino , Edad Gestacional , Humanos , Hipertensión/etiología , Preeclampsia/etiología , Embarazo , Complicaciones Cardiovasculares del Embarazo/etiología , Estadísticas no Paramétricas
15.
Ann Thorac Surg ; 70(3): 1086-9, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11016383

RESUMEN

BACKGROUND: Saphenous vein remains an elective conduit for up to 85% of coronary bypass operations. It is obtained through one or numerous skin incisions, with a reported morbidity varying from 5% to 25%. The endoscopic vein harvesting (EVH) technique was developed to minimize this morbidity and to improve clinical outcomes. The aim of this study was to review the feasibility of this method, its learning curve, and changing results in a group without previous experience in this procedure. METHODS: Between July 1998 and October 1999, 179 patients for coronary artery bypass grafting underwent EVH (Vasoview Guidant, USA "double access" and Uniport), by two operators. Results were reported based on time of harvesting, length of conduits, technical details, and clinical outcomes, and divided into six groups of 30 consecutive patients each. RESULTS: Patient demographics were as follows: 86.03% were male, aged 64.3+/-9.12 years (range, 43 to 92 years), with diabetes mellitus in 28.49%, obesity in 18.43%, and vascular disease in 11.17%. The EVH method was limited to the thigh in 77.65% of cases and extended to the leg in 22.35%. Patients received an average of 2.45+/-0.58 incisions and obtained conduits had a mean length of 34.96+/-9.65 cm (range, 15 to 70 cm). The number of venous bypasses per patient was 1.30+/-0.59. Mean time of EVH was 47.24+/-19.84 minutes (range, 15 to 120), with a length-time index of 0.85+/-0.36. Primary success was achieved in 95.54%, with crossover to open technique in 4.46%. General morbidity was 8.9%, with hematoma in 1.11%, skin necrosis in 1.11%, infection in 6.7%, and readmission in 1.11%. CONCLUSIONS: Endoscopic vein harvesting is a feasible and reproducible method, with a typical learning curve, acceptable morbidity, and unquestionable benefits for coronary artery bypass graft patients.


Asunto(s)
Endoscopía/métodos , Vena Safena/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Puente de Arteria Coronaria , Complicaciones de la Diabetes , Estudios de Factibilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Procedimientos Quirúrgicos Mínimamente Invasivos , Obesidad/complicaciones , Enfermedades Vasculares/complicaciones
16.
Hum Reprod ; 15(10): 2224-7, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11006204

RESUMEN

Nitric oxide (NO) has been found to be involved in the processes of cervical ripening. In a randomized, placebo-controlled study, cervical softening by an intracervical application of sodium nitroprusside, one of the most clinically potent and effective NO donor agents, was evaluated. A total of 36 primigravid women undergoing pregnancy termination between 9 and 12.5 weeks were enrolled. In one series, 18 patients were randomized to receive intracervically either placebo or 1% nitroprusside gel (5 mg), followed by uterine evacuation 6 h after treatment. In another series, 18 patients received either placebo or 2% nitroprusside gel (10 mg) into the cervical canal followed by uterine evacuation 3 h later. The cervical resistance, i.e. the force required to dilate the cervix from 3 to 10 mm, was the main outcome variable. It was recorded using a force sensing apparatus (dynamometer). Blood pressure was measured. Adverse events were recorded until 2 h after surgery. Women treated with both doses of nitroprusside gel showed values of cervical resistance significantly lower than those treated with placebo gel, at any tested diameter. No differences were found between subjects treated with the two different doses of nitroprusside. No significant consistent changes in blood pressure were induced by either dose of nitroprusside. No headaches were found in subjects treated with the NO donor. This study demonstrates that sodium nitroprusside applied into the cervical canal induces a rapid and significant softening of the cervix, thus reducing the force required to dilate it, compared with placebo-treated subjects. The chemical ripening of the cervix with sodium nitroprusside intracervical gel is an efficacious procedure in first-trimester pregnancy.


Asunto(s)
Maduración Cervical/efectos de los fármacos , Donantes de Óxido Nítrico/administración & dosificación , Nitroprusiato/administración & dosificación , Aborto Inducido , Administración Intravaginal , Adulto , Presión Sanguínea/efectos de los fármacos , Femenino , Geles/administración & dosificación , Humanos , Donantes de Óxido Nítrico/efectos adversos , Nitroprusiato/efectos adversos , Embarazo , Primer Trimestre del Embarazo
17.
Int J Tissue React ; 22(1): 1-4, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10937348

RESUMEN

Resveratrol is a grape component with complex pharmacology related to its antioxidant activity. Little is known about the direct effects of resveratrol on the myocardium. We tested whether resveratrol administration before ischemia could attenuate ischemic/reperfusion damage. We examined how resveratrol affects high-energy phosphate metabolism (31P-nuclear magnetic resonance) and contractility of isolated Langendorff perfused rat hearts subjected to 20 min no-flow ischemia and 30 min reperfusion. During 10 min resveratrol infusion (10 microM) before ischemia, basal phosphorylation potential dropped by 40% (p < 0.05 vs. preinfusion value) without affecting contractility. The level of effluent adenosine was increased by 68%, parallel to a 50% increase in coronary flow. Resveratrol significantly improved postischemic recovery of rate-pressure product (62 +/- 5.2 vs. 23 +/- 8.1% of controls; p < 0.05). The metabolic pattern following resveratrol infusion was similar to that produced by ischemic preconditioning, suggesting that an increase in adenosine availability is involved in cardioprotection.


Asunto(s)
Antioxidantes/farmacología , Corazón/efectos de los fármacos , Precondicionamiento Isquémico Miocárdico/métodos , Isquemia Miocárdica/tratamiento farmacológico , Miocardio/metabolismo , Recuperación de la Función/efectos de los fármacos , Estilbenos/farmacología , Adenosina/metabolismo , Animales , Fenómenos Fisiológicos Cardiovasculares/efectos de los fármacos , Masculino , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/fisiopatología , Infarto del Miocardio/prevención & control , Isquemia Miocárdica/metabolismo , Isquemia Miocárdica/prevención & control , Fosfatos/metabolismo , Fosforilación/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Flujo Sanguíneo Regional/efectos de los fármacos , Flujo Sanguíneo Regional/fisiología , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/metabolismo , Daño por Reperfusión/fisiopatología , Resveratrol
18.
Gynecol Endocrinol ; 14(2): 142-6, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10836202

RESUMEN

The aim of the study was to investigate the effects of estrogen replacement therapy (ERT) on nitric oxide (NO) activity in healthy postmenopausal women. The study group consisted of 22 postmenopausal women (last menses at least 12 months prior to study entry) who were randomized to receive treatment for 2 months with patches that delivered either 50 micrograms/day of 17 beta-estradiol or placebo in a cross-over design. Blood samples for measurements of serum citrulline and arginine were collected at the start of the study and at the end of each treatment course. Serum citrulline and arginine were measured using high-performance liquid chromatography with fluorometric detection. Arginine levels were significantly lower in the ERT group compared to the placebo group, while citrulline levels did not change. The percentage citrulline/arginine ratio was significantly higher in the ERT group (42.9 +/- 21.6) compared to the placebo group (33.9 +/- 18.5) (p < 0.01). The citrulline/arginine ratio, both at baseline and during either ERT or placebo administration demonstrated a positive linear correlation with body mass index (BMI). No correlations were found between follicle stimulating hormone, estradiol and insulin levels and BMI. No correlations were found between age, time since menopause and baseline arginine and citrulline levels or the citrulline/arginine ratio. These data indirectly demonstrate that transdermal estradiol replacement in postmenopausal women is able to stimulate NO production through the involvement of endogenous L-arginine. A positive linear correlation was found between BMI and the citrulline/arginine ratio, suggesting an additional protective cardiovascular effect in overweight women.


Asunto(s)
Terapia de Reemplazo de Estrógeno , Óxido Nítrico Sintasa/metabolismo , Posmenopausia , Arginina/sangre , Índice de Masa Corporal , Cromatografía Líquida de Alta Presión , Citrulina/sangre , Estudios Cruzados , Estradiol/administración & dosificación , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Persona de Mediana Edad , Placebos
19.
Cancer Res ; 60(7): 1793-6, 2000 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-10766159

RESUMEN

Endostatin, a Mr 20,000 fragment of collagen XVIII, potently inhibits the growth of experimental tumors implanted in mice. Here we report the cloning, expression, and antitumor activity of the rat form of endostatin. When tested on breast carcinomas arising in female virgin rats after intragastric administration of 9,10-dimethyl-1,2-benzanthracene (DMBA), endostatin induced significant inhibition of mammary tumor growth in all of the treated rats during a 4-week treatment period without signs of systemic toxicity. Interestingly, this arrest of tumor growth persisted throughout a four-week off-therapy period. Moreover, endostatin was effective in counteracting the development of multiple primary tumors. These results confirm that rat endostatin is a potent anticancer agent in a carcinogen-induced, spontaneously arising rat breast cancer model. It not only stops the growth of existing tumors but also decreases the incidence of the development of multiple neoplastic lesions.


Asunto(s)
Antineoplásicos/uso terapéutico , Colágeno/genética , Colágeno/uso terapéutico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/uso terapéutico , 9,10-Dimetil-1,2-benzantraceno , Secuencia de Aminoácidos , Animales , Antineoplásicos/química , Secuencia de Bases , Carcinógenos , Colágeno/química , Colágeno Tipo XVIII , Endostatinas , Femenino , Humanos , Neoplasias Mamarias Experimentales/inducido químicamente , Neoplasias Mamarias Experimentales/patología , Ratones , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/química , Proteínas Recombinantes/uso terapéutico , Alineación de Secuencia , Homología de Secuencia de Aminoácido
20.
Funct Neurol ; 15 Suppl 3: 137-42, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11200784

RESUMEN

It is well known that migraine is far more represented in females than in males. However, this gender-related difference is present only during reproductive life since in prepubertal children, migraine prevalence figures are independent of sex. Thus, transition to puberty accounts for changes which render females more susceptible to migraine attacks. In females, the main driver of the hormonal events allowing sexual maturation is the pulsatile secretion of hypothalamic LHRH modulated by opioid activity. Clinical reports suggest that migraine attacks could be prevented by the abolition of this neurohormonal secretion. On the other hand, several clinical and experimental observations have focused on neuroendocrine systems (opiatergic, serotonergic, adrenergic) as participating in the constitution of the so-called "migraine trait", the biological predisposition in patients that would explain their sensitivity to migraine triggers. Such neuroendocrine secretions are mainly dependent upon hypothalamic activity where a sexual dimorphic nucleus has been discovered in the preoptic area. We suggest that the sexual dimorphism of migraine should be sought in hypothalamic networks related to LHRH secretion.


Asunto(s)
Hipotálamo/fisiopatología , Trastornos Migrañosos/fisiopatología , Pubertad/fisiología , Adolescente , Niño , Femenino , Humanos , Masculino , Trastornos Migrañosos/epidemiología , Caracteres Sexuales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA